Pricing

With competition for follow-on-biologics on the upswing—and a potential market boom perhaps around the corner—continued education and course-setting for all stakeholders in charting the access landscape is paramount.

In this Pharmaceutical Executive video interview, Jesse Mendelsohn, senior vice president at Model N, talks about the influence of Medicare Part D drug price negotiations on manufacturer go-to-market strategies and decision-making, and the industry’s response to the wider dialogue on pricing transparency.

Amid lingering questions and uncertainty, a look at ways pharma companies can prioritize incorporating the Inflation Reduction Act into their strategic planning process—and do it now.

JAMA commentary suggests that issues such as high costs, access, and equity will stop patients from obtaining GLP-1 agonists to treat obesity.

Cardinal Health report highlights new biosimilar treatments, legislative developments, and multiple industry perspectives.

Amid shifting healthcare cost strategies, how manufacturers can apply past lessons to best support patients and help boost drug adherence.

As the market for biosimilars expands, a nuanced approach is needed to balance cost considerations with patient safety and pharmacovigilance efforts.

Higher prices of insulin attributed to significant annual increases, outpacing general inflation.

A look at how legislation—and the wider quest for more transparency on drug costs and reimbursement—may impact manufacturer product launch and pricing strategies in the years ahead.

Proposed legislation aims to address pharmacy benefit manager tactics to reduce prescription drug prices.

Novo Nordisk said it will continue providing Levemir vials and the Levemir FlexPen for diabetes control while supplies last, until the full product discontinuation at the end of 2024.

Eight rapid-, short-, and long-acting insulin products will move to tier one preferred status, which limits out-of-pocket spending to $35 or less for patients with diabetes.

Rubin speaks about how drugs aren’t being properly valued.

Webinar Date/Time: Thu, Oct 12, 2023 2:00 PM EDT

A phased launch approach may ultimately be more sustainable and enable maximum market penetration and commercial success with less upfront investment than traditional “go-for-broke” strategies.

In this exclusive Q&A, Vishali Amin, chief of staff to the office of the president and senior director of customer success for Kalderos, discusses the biggest hurdles to drug affordability, how patients can become aware of drug discounts, how drugs are selected for regulatory discount programs, and drug pricing strategies.

As we approach the one-year anniversary of the IRA being signed into law, questions remain about how the new law will reverberate changes across the biopharma industry.

Kevin Hagan, president and CEO of the PAN Foundation, discusses how pharma can help Medicare patients post-IRA reform.

Kevin Hagan, president and CEO of the PAN Foundation, spoke to PharmExec about the recent IRA changes to Medicare and how it positively effects patients.

Webinar Date/Time: Thu, Mar 16, 2023 11:00 AM EDT

Curative-type therapies offer great hope in further transforming treatments for cancer and other diseases, but addressing the economics of these products—and ultimately the cost-benefit equation—is daunting. What is being done to smooth the path for pricing and reimbursement?

Value-based price for access (VBPA) may increase access of specialty drugs for patients.

Ford discusses how rising drug costs in impact patients, and how they can either avoid them or find less-expensive options.

Its use enables key processes such as early access, regulatory approval, and reimbursement listing.

Upcoming regulatory changes to create new opportunity for specialized offerings.

Pharma and legal experts weigh in on the rush to secure intellectual property around psychedelic medicines, the value imperative that should govern pricing strategies, and the likely long-haul battle for more widespread decriminalization of these drugs.

As Congress struggles to reach agreement on funding for leading social and spending initiatives and to avoid default on government borrowing, the White House is emphasizing that reduced spending on prescription drugs can help offset some of the steep costs.

The Democratic proposal to authorize price negotiations on costly medicines covered by Medicare and to penalize firms that raise prices faster than inflation has drawn opposition pharma and biotech companies. More surprisingly, generic companies also are objecting to the changes on the table.

The 2021 National Reimbursement Drug List (NRDL) process has been unfolding in China since June this year, with several key themes emerging. Building on Simon-Kucher’s experience with the NRDL, the authors make three recommendations on negotiation strategies going into the process.

Democratic leaders in the House and Senate appear to have reached a compromise on a relatively modest plan for controlling prices on certain prescription drugs.